---
title: "投資者警示：Pomerantz 律師事務所代表 Capricor Therapeutics, Inc.（CAPR）的投資者進行索賠調查"
description: "Pomerantz 律師事務所正在代表 Capricor Therapeutics, Inc.（納斯達克代碼：CAPR）的投資者調查有關該公司及其高管潛在證券欺詐的索賠。在 2025 年 5 月 FDA 會議公告後，Capricor 的股票下跌了 29.13%。2025 年 6 月關於顧問委員會會議取消的後續報告導致股票價格進一步下跌 30.82%。鼓勵投資者聯繫 Pomerantz 以獲取更多信"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/252339374.md"
published_at: "2025-08-09T14:50:43.000Z"
---

# 投資者警示：Pomerantz 律師事務所代表 Capricor Therapeutics, Inc.（CAPR）的投資者進行索賠調查

> Pomerantz 律師事務所正在代表 Capricor Therapeutics, Inc.（納斯達克代碼：CAPR）的投資者調查有關該公司及其高管潛在證券欺詐的索賠。在 2025 年 5 月 FDA 會議公告後，Capricor 的股票下跌了 29.13%。2025 年 6 月關於顧問委員會會議取消的後續報告導致股票價格進一步下跌 30.82%。鼓勵投資者聯繫 Pomerantz 以獲取更多信息

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Capricor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

**\[Click here for information about joining the class action\]**

On May 5, 2025, Capricor issued a press release announcing that after “the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy”, the FDA had “confirmed its intent to hold an advisory committee meeting” in connection with the BLA.

On this news, Capricor’s stock price fell $3.00 per share, or 29.13%, to close at $7.30 per share on May 6, 2025.

Then, on June 20, 2025 the publication STAT reported that the new head of the relevant FDA unit had canceled the advisory committee meeting for deramiocel due to uncertainty about the drug’s efficacy and safety.

On this news, Capricor’s stock price fell $3.68 per share, or 30.82%, to close at $8.26 per share on June 20, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**CONTACT:**  
Danielle Peyton  
Pomerantz LLP  
dpeyton@pomlaw.com  
646-581-9980 ext. 7980

### Related Stocks

- [CAPR.US - Capricor治療](https://longbridge.com/zh-HK/quote/CAPR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4% | Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw a 69.4% decrease in short interest in December, with shares sold short tot | [Link](https://longbridge.com/zh-HK/news/270785955.md) |
| Capricor Therapeutics Unveils Investor Presentation Highlighting Duchenne Program and Exosome Platform | Capricor Therapeutics Inc. has released an investor presentation detailing updates on its Duchenne muscular dystrophy tr | [Link](https://longbridge.com/zh-HK/news/274992906.md) |
| How Investors May Respond To Capricor Therapeutics (CAPR) Phase 3 HOPE-3 Success And $150 Million Equity Raise | Capricor Therapeutics completed a $150 million public offering after positive Phase 3 HOPE-3 results for Deramiocel in D | [Link](https://longbridge.com/zh-HK/news/269428805.md) |
| Roth MKM Keeps Their Buy Rating on Capricor Therapeutics (CAPR) | Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Capricor Therapeutics with a $41 price target. The ana | [Link](https://longbridge.com/zh-HK/news/268620819.md) |
| Capricor Therapeutics Reports Positive Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy | Capricor Therapeutics announced positive Phase 3 results for Deramiocel in treating Duchenne muscular dystrophy. The HOP | [Link](https://longbridge.com/zh-HK/news/268427206.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。